The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
The LFNG gene (UniProt: Q8NES3) encodes beta-1,3-N-acetylglucosaminyltransferase lunatic fringe (EC 2.4.1.222) in humans (Homo sapiens). This protein is also known as O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase and belongs to the glycosyltransferase family 31 (GT31), specifically the Fringe subfamily (sparrow2006mutationofthe pages 4-5, c2024investigatingtherelationship pages 45-49). The gene identity has been confirmed across extensive literature, with no ambiguity regarding the target protein.
| Category | Key finding | Evidence and interpretation |
|---|---|---|
| Identity | Human LFNG, UniProt Q8NES3, encodes beta-1,3-N-acetylglucosaminyltransferase lunatic fringe (EC 2.4.1.222), also called O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase. It is a Fringe-family, glycosyltransferase-family-31 enzyme—not a similarly named protein from another organism. | Human genetic and biochemical studies identify LFNG as the Notch-modifying glycosyltransferase mutated in spondylocostal dysostosis type III (sparrow2006mutationofthe pages 4-5, wengryn2023functionalcharacterizationof pages 2-3, sparrow2006mutationofthe pages 1-2) |
| Architecture and family | Approximately 356 residues; an N-terminal membrane anchor supports Golgi residence, while the luminal C-terminal region contains the Fringe catalytic domain. Full-length and proteolytically processed forms can retain activity. | Domain architecture, processing, and activity are supported by recent functional work; the enzyme has a GT-A/Rossmann-like fold characteristic of metal-dependent, inverting glycosyltransferases (c2024investigatingtherelationship pages 45-49, wengryn2023functionalcharacterizationof pages 8-10) |
| Primary reaction | Transfers N-acetylglucosamine (GlcNAc) from UDP-GlcNAc to the 3-hydroxyl of an existing O-linked fucose, generating GlcNAc-β1,3-Fuc and UDP. | This is a fucose-specific β1,3-N-acetylglucosaminyltransferase reaction; UDP is released stoichiometrically (c2024investigatingtherelationship pages 45-49, sparrow2006mutationofthe pages 5-7) |
| Donor substrate | UDP-α-D-GlcNAc is the activated sugar donor. | Direct enzymatic assays used UDP-[³H]GlcNAc, while recent variant studies quantified UDP formation or GlcNAc transfer (wengryn2023functionalcharacterizationof pages 2-3, sparrow2006mutationofthe pages 5-7, c2024investigatingtherelationship pages 45-49) |
| Acceptor specificity | The physiological acceptors are O-fucose residues on selected epidermal-growth-factor-like repeats, especially within Notch receptor extracellular domains. LFNG therefore recognizes both the fucose and its folded EGF-repeat context rather than acting indiscriminately on all fucosylated glycans. | Notch1 glycoproteomic and biochemical studies show site-selective modification; not every O-fucosylated EGF repeat is equally modified (song2016lunaticmanicand pages 1-2, pennarubia2021modulationofthe pages 1-2) |
| Catalytic mechanism | LFNG is an inverting, metal-dependent GT-A glycosyltransferase. A DxD motif coordinates Mn²⁺ and the nucleotide-sugar donor; a catalytic Asp activates the fucose O3 nucleophile for an SN2-like attack on GlcNAc C1, producing inversion and a β linkage. | Proposed human-LFNG residues include the D200–D202 metal-binding motif, catalytic D290, and metal-coordinating H314; related GT31 structures support this conserved geometry, although some atomic details remain model-based rather than derived from a human LFNG ternary crystal structure (c2024investigatingtherelationship pages 45-49, kadirvelraj2021comparisonofhuman pages 4-5, kadirvelraj2021comparisonofhuman pages 6-7) |
| Functional compartment | LFNG acts principally in the Golgi lumen, where it modifies Notch receptors before their delivery to the plasma membrane. | Wild-type protein colocalizes with Golgi marker GM130. Mislocalized pathogenic variants lose processing or activity, strongly linking Golgi access to function; secretion observed after overexpression is not established as the principal physiological mode (sparrow2006mutationofthe pages 5-7, sparrow2006mutationofthe pages 4-5, wengryn2023functionalcharacterizationof pages 8-10, sparrow2006mutationofthe pages 1-2) |
| Position in Notch signaling | POFUT1 first installs O-fucose on folded Notch EGF repeats in the secretory pathway; LFNG then extends selected O-fucose glycans. At the cell surface, the altered receptor glycoform changes ligand binding and productive proteolysis, including ADAM-dependent S2 cleavage and γ-secretase-dependent NICD release. | LFNG is a receptor-modifying pathway tuner, not a Notch ligand or protease (yang2005fringeglycosyltransferasesdifferentially pages 1-2, yang2005fringeglycosyltransferasesdifferentially pages 2-4, yang2005fringeglycosyltransferasesdifferentially pages 8-10) |
| Ligand-selective effect | The best-established pattern is enhancement of DLL1/DLL4–Notch activation and attenuation of JAG1–Notch1 activation. Effects depend on receptor, modified EGF site, glycan extension, ligand presentation, and cell context; they should not be described as a universal binary switch. | LFNG increases productive Delta-induced binding/proteolysis, whereas Jagged can still bind yet trigger less efficient activation. Galactose extension of the Fringe-added GlcNAc can materially affect these outcomes (hou2012galactosedifferentiallymodulates pages 9-10, yang2005fringeglycosyltransferasesdifferentially pages 1-2, yuan2009functionsoflunatic pages 18-23) |
| Relationship to other Fringes | Mammals also express MFNG and RFNG. Their Notch-site preferences and ligand effects overlap but are not identical; in co-expression experiments, LFNG frequently exerted the dominant effect on Notch1 glycosylation and signaling. | Mass-spectrometric site mapping and cell-based signaling assays support a context-dependent hierarchy rather than complete redundancy (pennarubia2021modulationofthe pages 1-2) |
| Somitogenesis | Oscillatory LFNG expression in presomitic mesoderm is integrated into the Notch segmentation clock. LFNG helps synchronize signaling, establish somite boundaries and rostrocaudal polarity, and pattern the sclerotome that forms vertebrae and ribs. | Human genetics, mouse models, and contemporary segmentation-clock analyses identify LFNG as a central timing and patterning regulator (wengryn2023functionalcharacterizationof pages 1-2, c2024investigatingtherelationship pages 45-49, c2024investigatingtherelationship pages 40-45) |
| Mendelian disease | Biallelic pathogenic LFNG variants cause autosomal-recessive spondylocostal dysostosis type III (SCD3), characterized by congenital vertebral segmentation defects, malformed or fused ribs, short trunk or stature, scoliosis, and possible restrictive respiratory disease. | Variant mechanisms include catalytic loss, reduced activity, mislocalization, and impaired processing; the original F188L allele was mislocalized and enzymatically inactive (c2024investigatingtherelationship pages 66-71, sparrow2006mutationofthe pages 2-4, sparrow2006mutationofthe pages 5-7, wengryn2023functionalcharacterizationof pages 1-2) |
| 2023 variant development | Functional analysis of compound-heterozygous p.R174H and p.G256S found p.G256S enzymatically nonfunctional and p.R174H hypomorphic, while both retained Golgi localization and normal processing. | The work demonstrates that pathogenicity can result from quantitative catalytic impairment without trafficking failure and suggests that residual activity may modify some clinical features without preventing severe vertebral malformation (published July 2023) (wengryn2023functionalcharacterizationof pages 2-3, wengryn2023functionalcharacterizationof pages 8-10, wengryn2023functionalcharacterizationof pages 3-4, wengryn2023functionalcharacterizationof pages 1-2) |
| Hematopoiesis | LFNG strengthens Delta-like ligand responses in hematopoietic progenitors, supporting thymic T-lineage commitment and maturation. Its function overlaps with MFNG and RFNG rather than being absolutely indispensable in every immune context. | Fringe-null models show reduced DLL4 binding, weaker Notch-target expression, fewer early thymic and double-positive progenitors, and altered peripheral lymphocyte populations; restoration of LFNG can rescue major T-cell compartments (song2016lunaticmanicand pages 1-2, song2016lunaticmanicand pages 11-12, song2016lunaticmanicand pages 10-11) |
| Angiogenesis | In endothelial cells, LFNG tunes DLL4–Notch1-dependent tip/stalk selection, sprout dynamics, and endothelial–pericyte communication. BMP9–ALK1 signaling can regulate LFNG, linking vascular growth-factor and Notch pathways. | A 2024 donor-cell transcriptomic study validated impaired BMP9 regulation of LFNG in multiple ALK1-mutant endothelial models, but whether LFNG is causal in hereditary hemorrhagic telangiectasia or pulmonary arterial hypertension remains unresolved (published January 2024) (tabosh2024impactofheterozygous pages 13-14) |
| Cancer biology | LFNG has context-dependent cancer effects because it changes receptor- and ligand-specific Notch signaling. It has been reported as tumor suppressive in some settings but is associated with aggressive behavior in others, especially pancreatic adenocarcinoma. | A 33-cancer TCGA analysis associated high LFNG with poor outcomes in several cancers and experimentally found increased proliferation and invasion in LFNG-overexpressing PANC1 cells; these findings support biomarker potential but do not establish pan-cancer causality (published November 2023) (gong2023apancanceranalysis pages 6-10, gong2023apancanceranalysis pages 10-12, gong2023apancanceranalysis pages 1-2) |
| 2024–2025 pancreatic-cancer development | Recent mouse lineage-tracing and genetic experiments identified LFNG-expressing centroacinar cells as a transformation-susceptible population in KRAS-driven, p53-deficient pancreatic cancer. Lfng deletion inhibited tumor initiation and suppressed tumors arising from several exocrine lineages, with Notch3 implicated functionally. | Human PDAC LFNG abundance correlated with higher grade and poorer survival. The article was published in 2025 with a 2024 DOI record; it strengthens the case for LFNG as a context-specific therapeutic target but does not yet establish a validated human therapy (chung2025lfngexpressingcentroacinarcell pages 7-10, chung2025lfngexpressingcentroacinarcell pages 5-7, chung2025lfngexpressingcentroacinarcell pages 1-3) |
| Current applications | Present real-world utility is mainly molecular diagnosis and variant interpretation for SCD3, research assays of Notch glycosylation, disease modeling, and exploratory biomarker/target development in cancer and vascular biology. No LFNG-specific approved drug or established clinical LFNG-directed therapy was identified. | Functional assays that separately measure catalytic activity, Golgi localization, and processing are particularly useful for classifying rare LFNG variants and explaining genotype–phenotype differences (wengryn2023functionalcharacterizationof pages 2-3, wengryn2023functionalcharacterizationof pages 8-10, c2024investigatingtherelationship pages 133-137) |
| Evidence limitations | Human loss-of-function evidence is strongest for SCD3; many broader roles derive from mouse genetics, cultured cells, omics associations, or computational models. Ligand effects are site- and context-dependent, and precise human-LFNG structural determinants remain less directly resolved than the core reaction. | Conclusions about angiogenesis and cancer should therefore be treated as mechanistically plausible and experimentally supported, but not equivalent to validated clinical utility (yuan2009functionsoflunatic pages 18-23, gong2023apancanceranalysis pages 6-10, tabosh2024impactofheterozygous pages 13-14, kadirvelraj2021comparisonofhuman pages 4-5) |
Table: This table consolidates LFNG identity, enzymology, localization, Notch-pathway mechanism, developmental and disease roles, and major 2023–2025 findings. It distinguishes well-established biochemical and Mendelian evidence from emerging vascular and cancer applications.
LFNG functions as a β-1,3-N-acetylglucosaminyltransferase that catalyzes the transfer of N-acetylglucosamine (GlcNAc) from the donor substrate UDP-GlcNAc to O-fucose residues, forming a β-1,3-glycosidic linkage (sparrow2006mutationofthe pages 4-5, c2024investigatingtherelationship pages 45-49, sparrow2006mutationofthe pages 5-7). The complete reaction can be written as:
UDP-α-D-GlcNAc + O-Fucose-EGF-Notch → GlcNAc-β1,3-Fucose-EGF-Notch + UDP
This reaction releases UDP in a 1:1 stoichiometric ratio with product formation, which serves as a functional readout for enzymatic activity (c2024investigatingtherelationship pages 45-49).
The donor substrate is UDP-α-D-GlcNAc, which has been directly demonstrated using radiolabeled UDP-[³H]GlcNAc in enzymatic assays (sparrow2006mutationofthe pages 5-7, hou2012galactosedifferentiallymodulates pages 1-2).
The acceptor substrates are highly specific: LFNG recognizes O-fucose residues attached to serine or threonine residues within epidermal growth factor-like (EGF) repeats of Notch receptors (song2016lunaticmanicand pages 1-2, gomezUnknownyearmasterproject pages 6-10, pennarubia2021modulationofthe pages 1-2). Importantly, LFNG exhibits site-selectivity, as not all O-fucosylated EGF repeats are equally modified. This specificity reflects recognition of both the fucose moiety and the surrounding folded EGF-domain context (pennarubia2021modulationofthe pages 1-2).
LFNG employs an inverting, metal-dependent GT-A fold mechanism. The enzyme contains a conserved DxD motif (residues D200-D202 in human LFNG) that coordinates a divalent manganese ion (Mn²⁺) and positions the UDP-GlcNAc donor substrate (c2024investigatingtherelationship pages 45-49). The catalytic base D290 deprotonates the fucose O3 hydroxyl, enabling nucleophilic attack on the anomeric carbon of GlcNAc in an SN2-like displacement reaction, which inverts the stereochemistry from α to β configuration (c2024investigatingtherelationship pages 45-49, gomezUnknownyearmasterproject pages 23-30, gomezUnknownyearmasterproject pages 6-10). Additional catalytic residues include H314, which helps chelate Mn²⁺ and stabilize the active site architecture (c2024investigatingtherelationship pages 45-49).
The LFNG protein contains approximately 356 amino acids, with an N-terminal transmembrane domain that anchors it to the Golgi membrane and a C-terminal catalytic domain (residues 108-358) containing the Fringe domain responsible for enzymatic activity (c2024investigatingtherelationship pages 45-49, gomezUnknownyearmasterproject pages 6-10).
LFNG is localized to the Golgi apparatus, where it functions as a Golgi-resident glycosyltransferase (c2024investigatingtherelationship pages 45-49, sparrow2006mutationofthe pages 5-7, sparrow2006mutationofthe pages 4-5). The N-terminal transmembrane domain anchors the full-length protein within the Golgi lumen, positioning the catalytic domain to access Notch receptors as they transit through the secretory pathway (c2024investigatingtherelationship pages 45-49).
Experimental evidence demonstrates that wild-type LFNG colocalizes with the Golgi marker GM130 in transfected cells (sparrow2006mutationofthe pages 5-7, c2024investigatingtherelationship pages 88-92). Disease-associated mutations that disrupt Golgi localization, such as F188L, result in loss of enzymatic function and inability to modulate Notch signaling, emphasizing the critical importance of proper subcellular targeting (sparrow2006mutationofthe pages 5-7, sparrow2006mutationofthe pages 4-5, wengryn2023functionalcharacterizationof pages 8-10).
The protein can undergo proteolytic processing by the Golgi-resident protease SPC6, generating both full-length and processed forms, both of which retain catalytic activity (c2024investigatingtherelationship pages 45-49, wengryn2023functionalcharacterizationof pages 8-10). While secreted forms of LFNG have been detected following overexpression, the biologically relevant function occurs within the Golgi, where LFNG modifies Notch receptors before they reach the cell surface (sparrow2006mutationofthe pages 5-7, sparrow2006mutationofthe pages 1-2).
LFNG functions as a critical modulator of Notch receptor-ligand interactions rather than as a simple on/off switch for Notch signaling. The enzyme modifies O-fucose glycans on specific EGF repeats of Notch receptors, altering the receptor's affinity for different ligands and the efficiency of subsequent proteolytic activation (hou2012galactosedifferentiallymodulates pages 9-10, yang2005fringeglycosyltransferasesdifferentially pages 1-2, yuan2009functionsoflunatic pages 18-23).
The most well-established pattern is that LFNG enhances Notch1 activation by Delta-like ligands (DLL1 and DLL4) while attenuating activation by Jagged ligands (JAG1 and JAG2) (yang2005fringeglycosyltransferasesdifferentially pages 1-2, yuan2009functionsoflunatic pages 18-23, yuan2009functionsoflunatic pages 151-157, yang2005fringeglycosyltransferasesdifferentially pages 2-4). This differential modulation occurs through multiple mechanisms:
Altered ligand binding affinity: LFNG modification increases the binding of soluble DLL1 and DLL4 to Notch1, while maintaining or slightly increasing Jagged1 binding (hou2012galactosedifferentiallymodulates pages 9-10, ristori2026bmp9regulatesnotch pages 9-11).
Differential proteolytic efficiency: Even when Jagged1 can bind to LFNG-modified Notch1, the bound receptor is less efficiently processed by ADAM metalloprotease-mediated S2 cleavage, reducing generation of the Notch intracellular domain (NICD) and downstream transcriptional activation (yang2005fringeglycosyltransferasesdifferentially pages 1-2, yang2005fringeglycosyltransferasesdifferentially pages 2-4, yang2005fringeglycosyltransferasesdifferentially pages 8-10).
Context-dependent effects: The magnitude and direction of LFNG effects depend on the specific Notch receptor isoform, the particular EGF repeat modified, the extent of glycan extension (particularly galactose addition), ligand presentation mode, and cellular context (hou2012galactosedifferentiallymodulates pages 9-10, yuan2009functionsoflunatic pages 18-23).
Mammals express three Fringe glycosyltransferases: LFNG, MFNG (Manic Fringe), and RFNG (Radical Fringe). While all three can modify Notch receptors, they exhibit different site preferences and functional effects. In comparative studies, LFNG frequently exerts a dominant effect over MFNG and RFNG when co-expressed, particularly for Notch1 modification (pennarubia2021modulationofthe pages 1-2). Mass spectrometric glycoproteomic mapping demonstrates that individual Fringe enzymes modify distinct but overlapping sets of O-fucose sites on Notch (pennarubia2021modulationofthe pages 1-2).
The biological effects of LFNG modification can be further modulated by subsequent glycan extension. Addition of galactose to the Fringe-added GlcNAc by β1,4-galactosyltransferases (B4GALT1) enhances LFNG's positive effect on DLL1-induced Notch signaling but is required for LFNG-mediated inhibition of JAG1 signaling (hou2012galactosedifferentiallymodulates pages 9-10). This indicates that the complete O-fucose glycan structure, not just the initial GlcNAc addition, determines the functional outcome.
LFNG plays a central role in the vertebrate segmentation clock that controls somitogenesis during embryonic development (wengryn2023functionalcharacterizationof pages 1-2, c2024investigatingtherelationship pages 45-49, sparrow2006mutationofthe pages 1-2). In the presomitic mesoderm, LFNG expression oscillates with a periodicity matching somite formation, and this oscillatory expression is essential for proper segmentation (c2024investigatingtherelationship pages 45-49, c2024investigatingtherelationship pages 40-45).
The molecular mechanism involves LFNG-dependent modulation of Notch signaling dynamics: oscillatory LFNG expression promotes pulsatile Notch1-DLL1 interactions that drive anterior somite gene expression, while LFNG repression by HES7 allows sustained Notch1-DLL4 signaling required for posterior somite development (wengryn2023functionalcharacterizationof pages 1-2, c2024investigatingtherelationship pages 66-71). This temporal regulation establishes somite polarity, rostrocaudal organization, and proper boundaries between forming somites (c2024investigatingtherelationship pages 66-71, sparrow2006mutationofthe pages 2-4).
LFNG function is dosage-sensitive: different levels of LFNG activity produce varying numbers and morphologies of somites and vertebral bodies, with thoracic vertebrae requiring the highest LFNG potency (c2024investigatingtherelationship pages 45-49). The sclerotome derived from properly patterned somites subsequently forms the vertebrae and ribs, linking LFNG-dependent signaling to axial skeletal development (wengryn2023functionalcharacterizationof pages 1-2, c2024investigatingtherelationship pages 66-71).
Biallelic pathogenic variants in LFNG cause autosomal recessive spondylocostal dysostosis type III (SCD3), a severe skeletal dysplasia characterized by congenital vertebral segmentation defects, malformed or fused vertebrae (including hemivertebrae), abnormal ribs (missing, fused, or dysplastic), short trunk or stature, scoliosis, and potentially restrictive respiratory disease (c2024investigatingtherelationship pages 66-71, sparrow2006mutationofthe pages 2-4, wengryn2023functionalcharacterizationof pages 3-4, sparrow2006mutationofthe pages 1-2, wengryn2023functionalcharacterizationof pages 1-2).
The original reported mutation was a homozygous F188L substitution that resulted in Golgi mislocalization, complete loss of GlcNAc-transferase activity, and inability to modulate Notch signaling (sparrow2006mutationofthe pages 5-7, sparrow2006mutationofthe pages 2-4, sparrow2006mutationofthe pages 4-5). Functional studies demonstrated that this mutation disrupts a highly conserved phenylalanine near the enzyme's active site (sparrow2006mutationofthe pages 4-5, sparrow2006mutationofthe pages 5-7).
In July 2023, Wengryn et al. published functional characterization of two novel compound heterozygous LFNG variants: p.R174H and p.G256S (wengryn2023functionalcharacterizationof pages 2-3, wengryn2023functionalcharacterizationof pages 3-4, wengryn2023functionalcharacterizationof pages 1-2). Their findings revealed important mechanistic insights:
The hypomorphic p.R174H variant was associated with some phenotypic differences, including potentially improved stature (lower arm span-to-height ratio) and more vertebrae, suggesting that residual LFNG activity may modify certain clinical features without preventing severe vertebral malformations (wengryn2023functionalcharacterizationof pages 2-3, wengryn2023functionalcharacterizationof pages 1-2).
These findings establish that SCD3 pathogenic mechanisms include not only complete loss of function through mislocalization or catalytic inactivation, but also partial reduction in enzymatic activity (c2024investigatingtherelationship pages 66-71, c2024investigatingtherelationship pages 133-137).
LFNG plays important roles in T-cell development and hematopoiesis by modulating Notch signaling in thymic progenitors (yuan2009functionsoflunatic pages 173-182, yuan2009functionsoflunatic pages 145-151, song2016lunaticmanicand pages 1-2). LFNG strengthens Delta-like ligand (particularly DLL4) responses in hematopoietic stem and progenitor cells, promoting T-lineage commitment and suppressing alternative B-cell and myeloid fates (yuan2009functionsoflunatic pages 173-182, yuan2009functionsoflunatic pages 136-145).
In thymic development, LFNG enhances the competitive fitness of T-cell progenitors by increasing their sensitivity to limiting Notch signals, thereby promoting progression through double-negative (DN) to double-positive (DP) stages (yuan2009functionsoflunatic pages 145-151, song2016lunaticmanicand pages 1-2). Loss of all three Fringe genes (LFNG, MFNG, and RFNG) results in reduced DLL4 binding to early thymic progenitors, decreased Notch target gene expression, fewer DN1, DN2, and DP precursors, and altered proportions of mature CD4⁺ and CD8⁺ single-positive T cells (song2016lunaticmanicand pages 1-2, song2016lunaticmanicand pages 11-12).
However, LFNG is not absolutely essential for T-cell development, as its function partially overlaps with MFNG and RFNG. Expression of any single Fringe gene can support normal proportions of major T- and B-cell populations, although combined loss impairs T-cell activation, proliferation, and generates immune defects (song2016lunaticmanicand pages 12-13, song2016lunaticmanicand pages 11-12, song2016lunaticmanicand pages 10-11).
LFNG functions as a critical regulator of endothelial Notch signaling during angiogenesis, controlling tip/stalk cell selection, vessel branching, and vascular patterning (ristori2026bmp9regulatesnotch pages 23-28, ristori2026bmp9regulatesnotch pages 3-5, ristori2026bmp9regulatesnotch pages 1-3). The enzyme influences the temporal dynamics of angiogenic sprouting by modulating Dll4-Notch1 binding affinity and activation kinetics (ristori2026bmp9regulatesnotch pages 7-9, ristori2026bmp9regulatesnotch pages 5-7).
Recent research has identified an important regulatory pathway linking BMP9/ALK1 signaling to LFNG expression in endothelial cells (ristori2026bmp9regulatesnotch pages 3-5, ristori2026bmp9regulatesnotch pages 11-13, ristori2026bmp9regulatesnotch pages 1-3). BMP9 rapidly and transiently induces LFNG through SMAD1/5 signaling, which in turn enhances Dll4-mediated Notch1 activation and regulates the timing of tip/stalk cell selection (ristori2026bmp9regulatesnotch pages 3-5, ristori2026bmp9regulatesnotch pages 5-7). This pathway coordinates multiple aspects of vascular development:
Temporal regulation: LFNG controls the pace of tip cell selection and the frequency of tip/stalk cell rearrangement or "shuffling" during sprout formation (ristori2026bmp9regulatesnotch pages 23-28, ristori2026bmp9regulatesnotch pages 7-9)
Spatial patterning: Loss of LFNG increases tip cell selection, vascular density, and sprout length, while reducing the spacing between branches (ristori2026bmp9regulatesnotch pages 23-28, ristori2026bmp9regulatesnotch pages 5-7)
Endothelial-pericyte communication: LFNG enhances Dll4-Notch1 signaling in endothelial cells while redirecting Jag1 toward Notch3 activation in pericytes, promoting vessel stabilization and pericyte coverage (ristori2026bmp9regulatesnotch pages 9-11, ristori2026bmp9regulatesnotch pages 11-13)
A January 2024 study by Tabosh et al. investigated the transcriptomic response to BMP9/BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH) patients carrying heterozygous ALK1 mutations (tabosh2024impactofheterozygous pages 13-14). The study found that LFNG regulation by BMP9 was impaired in some ALK1-mutated endothelial cell models, and reduced Lfng expression was observed in mouse HHT models. However, the authors emphasized that the precise causal role of LFNG dysregulation in HHT/PAH pathogenesis requires further investigation (tabosh2024impactofheterozygous pages 13-14).
In mosaic vessel modeling, LFNG-deficient cells preferentially accumulate at vessel tips and form abnormal vascular structures, potentially contributing to arteriovenous malformation development (ristori2026bmp9regulatesnotch pages 23-28, ristori2026bmp9regulatesnotch pages 7-9).
LFNG exhibits context-dependent and sometimes opposing roles in cancer, reflecting its fundamental function as a modulator of ligand-specific Notch signaling. The enzyme has been reported as tumor suppressive in some cancers (breast, prostate, cervical) but is associated with aggressive disease and poor prognosis in others (liver, colorectal, lung, pancreatic) (gong2023apancanceranalysis pages 1-2).
A comprehensive pan-cancer analysis published in November 2023 by Gong et al. examined LFNG expression across 33 cancer types from The Cancer Genome Atlas (gong2023apancanceranalysis pages 6-10, gong2023apancanceranalysis pages 12-14, gong2023apancanceranalysis pages 10-12, gong2023apancanceranalysis pages 1-2). Key findings included:
High LFNG expression was associated with poor overall survival in multiple cancers, particularly pancreatic adenocarcinoma (PAAD), uveal melanoma, lower-grade glioma, and mesothelioma (gong2023apancanceranalysis pages 6-10)
LFNG expression correlated with copy number variation (positive correlation) and DNA methylation (negative correlation), indicating genomic and epigenetic regulation (gong2023apancanceranalysis pages 6-10)
Reduced immune cell infiltration: High LFNG expression was negatively correlated with tumor-infiltrating lymphocytes, especially T cells, suggesting an immunosuppressive microenvironment (gong2023apancanceranalysis pages 6-10, gong2023apancanceranalysis pages 12-14)
In vitro experiments with PANC1 pancreatic cancer cells demonstrated that LFNG overexpression increased proliferation, migration, invasion, and pseudopodia formation, while altering cell cycle progression (gong2023apancanceranalysis pages 10-12)
In a clinical PAAD cohort, high LFNG expression was associated with advanced T stage, poor differentiation, higher pathological grade, distant metastasis, and significantly worse overall survival (gong2023apancanceranalysis pages 10-12)
Groundbreaking research published in 2025 by Chung et al. identified LFNG as a marker of a unique cell-of-origin for p53-deficient pancreatic ductal adenocarcinoma (PDAC) (chung2025lfngexpressingcentroacinarcell pages 7-10, chung2025lfngexpressingcentroacinarcell pages 5-7, chung2025lfngexpressingcentroacinarcell pages 3-4, chung2025lfngexpressingcentroacinarcell pages 1-3). Using lineage-tracing approaches in mice, the study revealed:
LFNG marks a limited population of centroacinar cells in the adult pancreas that are particularly susceptible to transformation when oncogenic KRAS is combined with p53 loss (chung2025lfngexpressingcentroacinarcell pages 3-4, chung2025lfngexpressingcentroacinarcell pages 1-3)
Genetic deletion of Lfng blocked tumor initiation from LFNG-expressing centroacinar cells and suppressed tumors arising from acinar- and ductal-derived lineages (chung2025lfngexpressingcentroacinarcell pages 7-10, chung2025lfngexpressingcentroacinarcell pages 1-3)
Notch3 was identified as the functional Notch receptor mediating LFNG-dependent PDAC initiation and progression in this model (chung2025lfngexpressingcentroacinarcell pages 7-10, chung2025lfngexpressingcentroacinarcell pages 5-7)
LFNG deletion reduced proliferation, altered cell fate toward acinar differentiation, and improved survival in multiple PDAC mouse models (chung2025lfngexpressingcentroacinarcell pages 5-7)
In human PDAC tissues, LFNG expression positively correlated with tumor grade and high LFNG was associated with shorter overall survival (chung2025lfngexpressingcentroacinarcell pages 5-7, chung2025lfngexpressingcentroacinarcell pages 1-3)
These findings establish LFNG as a potential therapeutic target in PDAC, though they also highlight context-dependency, as earlier mouse models had suggested tumor-suppressive roles (chung2025lfngexpressingcentroacinarcell pages 1-3).
The primary established real-world application of LFNG research is molecular diagnosis and variant interpretation for spondylocostal dysostosis type III. Functional assays that measure glycosyltransferase activity, Golgi localization, and protein processing are particularly valuable for classifying rare LFNG variants and explaining genotype-phenotype correlations (wengryn2023functionalcharacterizationof pages 2-3, wengryn2023functionalcharacterizationof pages 8-10, c2024investigatingtherelationship pages 133-137).
Beyond genetic diagnosis, LFNG has several emerging applications:
Biomarker development: LFNG expression shows potential as a prognostic biomarker in pancreatic cancer and other malignancies (gong2023apancanceranalysis pages 6-10, gong2023apancanceranalysis pages 10-12, chung2025lfngexpressingcentroacinarcell pages 5-7)
Research tools: LFNG is used extensively in basic research to study Notch glycosylation, signaling dynamics, and disease modeling (pennarubia2021modulationofthe pages 1-2, yuan2009functionsoflunatic pages 18-23)
Therapeutic target exploration: LFNG represents a potential therapeutic target in specific cancer contexts, particularly PDAC, though no LFNG-specific drugs are currently in clinical use (chung2025lfngexpressingcentroacinarcell pages 1-3)
It is important to note the following limitations:
Human loss-of-function evidence is strongest for SCD3, with over 300 citations for the seminal 2006 paper (sparrow2006mutationofthe pages 4-5)
Many broader roles in angiogenesis, hematopoiesis, and cancer derive primarily from mouse genetics, cell culture systems, transcriptomic associations, or computational models rather than direct human genetic evidence (yuan2009functionsoflunatic pages 18-23, gong2023apancanceranalysis pages 6-10, tabosh2024impactofheterozygous pages 13-14)
Ligand-specific effects are context-dependent, varying with receptor isoform, EGF repeat, glycan extension, ligand presentation, and cellular environment (hou2012galactosedifferentiallymodulates pages 9-10, yuan2009functionsoflunatic pages 18-23)
Precise human LFNG structural determinants remain partially model-based, as detailed atomic structures derive from related family members like mouse Manic Fringe rather than complete human LFNG crystal structures (kadirvelraj2021comparisonofhuman pages 4-5, kadirvelraj2021comparisonofhuman pages 6-7)
Contemporary understanding positions LFNG as a context-dependent fine-tuner of Notch signaling rather than an absolute on/off switch. As emphasized by recent reviews, the enzyme's effects depend critically on which Notch receptor, which ligand, which EGF repeat, and which cellular context is examined (yuan2009functionsoflunatic pages 18-23). This nuanced view has replaced earlier simplified models.
The 2021 work by Pennarubia et al. demonstrated that when multiple Fringe enzymes are co-expressed, LFNG exerts a dominant effect over MFNG and RFNG, particularly for Notch1 modification, establishing a functional hierarchy among mammalian Fringe proteins (pennarubia2021modulationofthe pages 1-2).
Recent mechanistic studies emphasize that LFNG's biological effects extend beyond simple enhancement or suppression of Notch signaling to include temporal regulation of signaling dynamics, which is particularly important in oscillatory systems like the segmentation clock and in dynamic processes like angiogenic sprouting (c2024investigatingtherelationship pages 45-49, ristori2026bmp9regulatesnotch pages 23-28, ristori2026bmp9regulatesnotch pages 7-9).
LFNG (Q8NES3) encodes a Golgi-localized β-1,3-N-acetylglucosaminyltransferase that modifies O-fucose residues on Notch receptor EGF repeats, functioning as a critical regulator of Notch signaling in development, immunity, and disease. The enzyme catalyzes GlcNAc transfer from UDP-GlcNAc to O-fucose through an inverting, metal-dependent mechanism, preferentially enhancing Delta-like ligand-induced Notch activation while suppressing Jagged ligand responses.
Loss-of-function mutations cause spondylocostal dysostosis type III, with recent 2023 studies identifying the first hypomorphic alleles and demonstrating that pathogenicity can result from quantitative catalytic impairment without trafficking defects. Beyond skeletal development, LFNG plays important roles in T-cell development, angiogenesis, and cancer biology.
Recent developments (2023-2025) have particularly advanced understanding of LFNG in pancreatic cancer, where it marks transformation-susceptible centroacinar cells and functions as an oncogene through Notch3 signaling, and in vascular biology, where the BMP9-LFNG-Notch axis regulates endothelial patterning and may contribute to hereditary hemorrhagic telangiectasia pathogenesis. While established clinical applications focus on genetic diagnosis of SCD3, emerging evidence supports potential roles as a cancer biomarker and therapeutic target, though these applications require further validation.
References
(sparrow2006mutationofthe pages 4-5): D.B. Sparrow, G. Chapman, M.A. Wouters, N.V. Whittock, S. Ellard, D. Fatkin, P.D. Turnpenny, K. Kusumi, D. Sillence, and S.L. Dunwoodie. Mutation of the lunatic fringe gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. American journal of human genetics, 78 1:28-37, Jan 2006. URL: https://doi.org/10.1086/498879, doi:10.1086/498879. This article has 304 citations and is from a highest quality peer-reviewed journal.
(c2024investigatingtherelationship pages 45-49): Parker C Wengryn. Investigating the relationship between lunatic fringe variants and spondylocostal dysostosis type-iii. Text, 2024. URL: https://doi.org/10.7939/r3-ws3a-6886, doi:10.7939/r3-ws3a-6886. This article has 0 citations and is from a peer-reviewed journal.
(wengryn2023functionalcharacterizationof pages 2-3): Parker Wengryn, Karina da Costa Silveira, Connor Oborn, Carrie-Lynn Soltys, Alexander Beke, Inara Chacon-Fonseca, Nadirah Damseh, Marco Quesada Rodriguez, Ramses Badilla-Porras, and Peter Kannu. Functional characterization of novel lunatic fringe variants in spondylocostal dysostosis type-iii with scoliosis. Human Mutation, 2023:1-12, Jul 2023. URL: https://doi.org/10.1155/2023/5989733, doi:10.1155/2023/5989733. This article has 3 citations and is from a domain leading peer-reviewed journal.
(sparrow2006mutationofthe pages 1-2): D.B. Sparrow, G. Chapman, M.A. Wouters, N.V. Whittock, S. Ellard, D. Fatkin, P.D. Turnpenny, K. Kusumi, D. Sillence, and S.L. Dunwoodie. Mutation of the lunatic fringe gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. American journal of human genetics, 78 1:28-37, Jan 2006. URL: https://doi.org/10.1086/498879, doi:10.1086/498879. This article has 304 citations and is from a highest quality peer-reviewed journal.
(wengryn2023functionalcharacterizationof pages 8-10): Parker Wengryn, Karina da Costa Silveira, Connor Oborn, Carrie-Lynn Soltys, Alexander Beke, Inara Chacon-Fonseca, Nadirah Damseh, Marco Quesada Rodriguez, Ramses Badilla-Porras, and Peter Kannu. Functional characterization of novel lunatic fringe variants in spondylocostal dysostosis type-iii with scoliosis. Human Mutation, 2023:1-12, Jul 2023. URL: https://doi.org/10.1155/2023/5989733, doi:10.1155/2023/5989733. This article has 3 citations and is from a domain leading peer-reviewed journal.
(sparrow2006mutationofthe pages 5-7): D.B. Sparrow, G. Chapman, M.A. Wouters, N.V. Whittock, S. Ellard, D. Fatkin, P.D. Turnpenny, K. Kusumi, D. Sillence, and S.L. Dunwoodie. Mutation of the lunatic fringe gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. American journal of human genetics, 78 1:28-37, Jan 2006. URL: https://doi.org/10.1086/498879, doi:10.1086/498879. This article has 304 citations and is from a highest quality peer-reviewed journal.
(song2016lunaticmanicand pages 1-2): Yinghui Song, Vivek Kumar, Hua-Xing Wei, Ju Qiu, and Pamela Stanley. Lunatic, manic, and radical fringe each promote t and b cell development. The Journal of Immunology, 196:232-243, Jan 2016. URL: https://doi.org/10.4049/jimmunol.1402421, doi:10.4049/jimmunol.1402421. This article has 58 citations.
(pennarubia2021modulationofthe pages 1-2): Florian Pennarubia, Alison V. Nairn, Megumi Takeuchi, Kelley W. Moremen, and Robert S. Haltiwanger. Modulation of the notch1 pathway by lunatic fringe is dominant over that of manic or radical fringe. Molecules, 26:5942, Sep 2021. URL: https://doi.org/10.3390/molecules26195942, doi:10.3390/molecules26195942. This article has 18 citations.
(kadirvelraj2021comparisonofhuman pages 4-5): Renuka Kadirvelraj, Jeong-Yeh Yang, Hyun W. Kim, Justin H. Sanders, Kelley W. Moremen, and Zachary A. Wood. Comparison of human poly-n-acetyl-lactosamine synthase structure with gt-a fold glycosyltransferases supports a modular assembly of catalytic subsites. Jan 2021. URL: https://doi.org/10.1074/jbc.ra120.015305, doi:10.1074/jbc.ra120.015305. This article has 49 citations and is from a domain leading peer-reviewed journal.
(kadirvelraj2021comparisonofhuman pages 6-7): Renuka Kadirvelraj, Jeong-Yeh Yang, Hyun W. Kim, Justin H. Sanders, Kelley W. Moremen, and Zachary A. Wood. Comparison of human poly-n-acetyl-lactosamine synthase structure with gt-a fold glycosyltransferases supports a modular assembly of catalytic subsites. Jan 2021. URL: https://doi.org/10.1074/jbc.ra120.015305, doi:10.1074/jbc.ra120.015305. This article has 49 citations and is from a domain leading peer-reviewed journal.
(yang2005fringeglycosyltransferasesdifferentially pages 1-2): Liang-Tung Yang, James T. Nichols, Christine Yao, Jennifer O. Manilay, Ellen A. Robey, and Gerry Weinmaster. Fringe glycosyltransferases differentially modulate notch1 proteolysis induced by delta1 and jagged1. Feb 2005. URL: https://doi.org/10.1091/mbc.e04-07-0614, doi:10.1091/mbc.e04-07-0614. This article has 285 citations and is from a domain leading peer-reviewed journal.
(yang2005fringeglycosyltransferasesdifferentially pages 2-4): Liang-Tung Yang, James T. Nichols, Christine Yao, Jennifer O. Manilay, Ellen A. Robey, and Gerry Weinmaster. Fringe glycosyltransferases differentially modulate notch1 proteolysis induced by delta1 and jagged1. Feb 2005. URL: https://doi.org/10.1091/mbc.e04-07-0614, doi:10.1091/mbc.e04-07-0614. This article has 285 citations and is from a domain leading peer-reviewed journal.
(yang2005fringeglycosyltransferasesdifferentially pages 8-10): Liang-Tung Yang, James T. Nichols, Christine Yao, Jennifer O. Manilay, Ellen A. Robey, and Gerry Weinmaster. Fringe glycosyltransferases differentially modulate notch1 proteolysis induced by delta1 and jagged1. Feb 2005. URL: https://doi.org/10.1091/mbc.e04-07-0614, doi:10.1091/mbc.e04-07-0614. This article has 285 citations and is from a domain leading peer-reviewed journal.
(hou2012galactosedifferentiallymodulates pages 9-10): Xinghua Hou, Yuko Tashima, and Pamela Stanley. Galactose differentially modulates lunatic and manic fringe effects on delta1-induced notch signaling. Journal of Biological Chemistry, 287:474-483, Jan 2012. URL: https://doi.org/10.1074/jbc.m111.317578, doi:10.1074/jbc.m111.317578. This article has 42 citations and is from a domain leading peer-reviewed journal.
(yuan2009functionsoflunatic pages 18-23): JS Yuan. Functions of lunatic and manic fringe in regulating the strength and specificity of notch receptor-ligand interactions during hematopoiesis. Unknown journal, 2009.
(wengryn2023functionalcharacterizationof pages 1-2): Parker Wengryn, Karina da Costa Silveira, Connor Oborn, Carrie-Lynn Soltys, Alexander Beke, Inara Chacon-Fonseca, Nadirah Damseh, Marco Quesada Rodriguez, Ramses Badilla-Porras, and Peter Kannu. Functional characterization of novel lunatic fringe variants in spondylocostal dysostosis type-iii with scoliosis. Human Mutation, 2023:1-12, Jul 2023. URL: https://doi.org/10.1155/2023/5989733, doi:10.1155/2023/5989733. This article has 3 citations and is from a domain leading peer-reviewed journal.
(c2024investigatingtherelationship pages 40-45): Parker C Wengryn. Investigating the relationship between lunatic fringe variants and spondylocostal dysostosis type-iii. Text, 2024. URL: https://doi.org/10.7939/r3-ws3a-6886, doi:10.7939/r3-ws3a-6886. This article has 0 citations and is from a peer-reviewed journal.
(c2024investigatingtherelationship pages 66-71): Parker C Wengryn. Investigating the relationship between lunatic fringe variants and spondylocostal dysostosis type-iii. Text, 2024. URL: https://doi.org/10.7939/r3-ws3a-6886, doi:10.7939/r3-ws3a-6886. This article has 0 citations and is from a peer-reviewed journal.
(sparrow2006mutationofthe pages 2-4): D.B. Sparrow, G. Chapman, M.A. Wouters, N.V. Whittock, S. Ellard, D. Fatkin, P.D. Turnpenny, K. Kusumi, D. Sillence, and S.L. Dunwoodie. Mutation of the lunatic fringe gene in humans causes spondylocostal dysostosis with a severe vertebral phenotype. American journal of human genetics, 78 1:28-37, Jan 2006. URL: https://doi.org/10.1086/498879, doi:10.1086/498879. This article has 304 citations and is from a highest quality peer-reviewed journal.
(wengryn2023functionalcharacterizationof pages 3-4): Parker Wengryn, Karina da Costa Silveira, Connor Oborn, Carrie-Lynn Soltys, Alexander Beke, Inara Chacon-Fonseca, Nadirah Damseh, Marco Quesada Rodriguez, Ramses Badilla-Porras, and Peter Kannu. Functional characterization of novel lunatic fringe variants in spondylocostal dysostosis type-iii with scoliosis. Human Mutation, 2023:1-12, Jul 2023. URL: https://doi.org/10.1155/2023/5989733, doi:10.1155/2023/5989733. This article has 3 citations and is from a domain leading peer-reviewed journal.
(song2016lunaticmanicand pages 11-12): Yinghui Song, Vivek Kumar, Hua-Xing Wei, Ju Qiu, and Pamela Stanley. Lunatic, manic, and radical fringe each promote t and b cell development. The Journal of Immunology, 196:232-243, Jan 2016. URL: https://doi.org/10.4049/jimmunol.1402421, doi:10.4049/jimmunol.1402421. This article has 58 citations.
(song2016lunaticmanicand pages 10-11): Yinghui Song, Vivek Kumar, Hua-Xing Wei, Ju Qiu, and Pamela Stanley. Lunatic, manic, and radical fringe each promote t and b cell development. The Journal of Immunology, 196:232-243, Jan 2016. URL: https://doi.org/10.4049/jimmunol.1402421, doi:10.4049/jimmunol.1402421. This article has 58 citations.
(tabosh2024impactofheterozygous pages 13-14): T. Al Tabosh, H. Liu, D. Koça, M. Al Tarrass, L. Tu, S. Giraud, L. Delagrange, M. Beaudoin, S. Rivière, V. Grobost, M. Rondeau-Lutz, O. Dupuis, N. Ricard, E. Tillet, P. Machillot, A. Salomon, C. Picart, C. Battail, S. Dupuis-Girod, C. Guignabert, A. Desroches-Castan, and S. Bailly. Impact of heterozygous alk1 mutations on the transcriptomic response to bmp9 and bmp10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors. Angiogenesis, 27:211-227, Jan 2024. URL: https://doi.org/10.1007/s10456-023-09902-8, doi:10.1007/s10456-023-09902-8. This article has 33 citations and is from a domain leading peer-reviewed journal.
(gong2023apancanceranalysis pages 6-10): Xun Gong, Chenglong Zheng, Haiying Jia, Yangruiyu Liu, Rui Yang, Zizhou Chen, Yihang Pan, Xiaowu Li, and Yuchen Liu. A pan-cancer analysis revealing the role of lfng, mfng and rfng in tumor prognosis and microenvironment. BMC Cancer, Nov 2023. URL: https://doi.org/10.1186/s12885-023-11545-3, doi:10.1186/s12885-023-11545-3. This article has 9 citations and is from a peer-reviewed journal.
(gong2023apancanceranalysis pages 10-12): Xun Gong, Chenglong Zheng, Haiying Jia, Yangruiyu Liu, Rui Yang, Zizhou Chen, Yihang Pan, Xiaowu Li, and Yuchen Liu. A pan-cancer analysis revealing the role of lfng, mfng and rfng in tumor prognosis and microenvironment. BMC Cancer, Nov 2023. URL: https://doi.org/10.1186/s12885-023-11545-3, doi:10.1186/s12885-023-11545-3. This article has 9 citations and is from a peer-reviewed journal.
(gong2023apancanceranalysis pages 1-2): Xun Gong, Chenglong Zheng, Haiying Jia, Yangruiyu Liu, Rui Yang, Zizhou Chen, Yihang Pan, Xiaowu Li, and Yuchen Liu. A pan-cancer analysis revealing the role of lfng, mfng and rfng in tumor prognosis and microenvironment. BMC Cancer, Nov 2023. URL: https://doi.org/10.1186/s12885-023-11545-3, doi:10.1186/s12885-023-11545-3. This article has 9 citations and is from a peer-reviewed journal.
(chung2025lfngexpressingcentroacinarcell pages 7-10): Wen-Cheng Chung, Shubing Zhang, Azeddine Atfi, and Keli Xu. Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. Oncogene, 44:348-362, Nov 2025. URL: https://doi.org/10.1038/s41388-024-03226-7, doi:10.1038/s41388-024-03226-7. This article has 2 citations and is from a domain leading peer-reviewed journal.
(chung2025lfngexpressingcentroacinarcell pages 5-7): Wen-Cheng Chung, Shubing Zhang, Azeddine Atfi, and Keli Xu. Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. Oncogene, 44:348-362, Nov 2025. URL: https://doi.org/10.1038/s41388-024-03226-7, doi:10.1038/s41388-024-03226-7. This article has 2 citations and is from a domain leading peer-reviewed journal.
(chung2025lfngexpressingcentroacinarcell pages 1-3): Wen-Cheng Chung, Shubing Zhang, Azeddine Atfi, and Keli Xu. Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. Oncogene, 44:348-362, Nov 2025. URL: https://doi.org/10.1038/s41388-024-03226-7, doi:10.1038/s41388-024-03226-7. This article has 2 citations and is from a domain leading peer-reviewed journal.
(c2024investigatingtherelationship pages 133-137): Parker C Wengryn. Investigating the relationship between lunatic fringe variants and spondylocostal dysostosis type-iii. Text, 2024. URL: https://doi.org/10.7939/r3-ws3a-6886, doi:10.7939/r3-ws3a-6886. This article has 0 citations and is from a peer-reviewed journal.
(hou2012galactosedifferentiallymodulates pages 1-2): Xinghua Hou, Yuko Tashima, and Pamela Stanley. Galactose differentially modulates lunatic and manic fringe effects on delta1-induced notch signaling. Journal of Biological Chemistry, 287:474-483, Jan 2012. URL: https://doi.org/10.1074/jbc.m111.317578, doi:10.1074/jbc.m111.317578. This article has 42 citations and is from a domain leading peer-reviewed journal.
(gomezUnknownyearmasterproject pages 6-10): AM Gómez and PM Filella. Master project. Unknown journal, Unknown year.
(gomezUnknownyearmasterproject pages 23-30): AM Gómez and PM Filella. Master project. Unknown journal, Unknown year.
(c2024investigatingtherelationship pages 88-92): Parker C Wengryn. Investigating the relationship between lunatic fringe variants and spondylocostal dysostosis type-iii. Text, 2024. URL: https://doi.org/10.7939/r3-ws3a-6886, doi:10.7939/r3-ws3a-6886. This article has 0 citations and is from a peer-reviewed journal.
(yuan2009functionsoflunatic pages 151-157): JS Yuan. Functions of lunatic and manic fringe in regulating the strength and specificity of notch receptor-ligand interactions during hematopoiesis. Unknown journal, 2009.
(ristori2026bmp9regulatesnotch pages 9-11): Tommaso Ristori, Raphael Thuret, Erika Hooker, Peter Quicke, Kevin Lanthier, Kalonji Ntumba, Irene M. Aspalter, Marina Uroz, Shane P. Herbert, Christopher S. Chen, Bruno Larrivée, and Katie Bentley. Bmp9 regulates notch signaling and the temporal dynamics of angiogenesis via lunatic fringe. bioRxiv, Sep 2026. URL: https://doi.org/10.1101/2023.09.25.557123, doi:10.1101/2023.09.25.557123. This article has 11 citations.
(yuan2009functionsoflunatic pages 173-182): JS Yuan. Functions of lunatic and manic fringe in regulating the strength and specificity of notch receptor-ligand interactions during hematopoiesis. Unknown journal, 2009.
(yuan2009functionsoflunatic pages 145-151): JS Yuan. Functions of lunatic and manic fringe in regulating the strength and specificity of notch receptor-ligand interactions during hematopoiesis. Unknown journal, 2009.
(yuan2009functionsoflunatic pages 136-145): JS Yuan. Functions of lunatic and manic fringe in regulating the strength and specificity of notch receptor-ligand interactions during hematopoiesis. Unknown journal, 2009.
(song2016lunaticmanicand pages 12-13): Yinghui Song, Vivek Kumar, Hua-Xing Wei, Ju Qiu, and Pamela Stanley. Lunatic, manic, and radical fringe each promote t and b cell development. The Journal of Immunology, 196:232-243, Jan 2016. URL: https://doi.org/10.4049/jimmunol.1402421, doi:10.4049/jimmunol.1402421. This article has 58 citations.
(ristori2026bmp9regulatesnotch pages 23-28): Tommaso Ristori, Raphael Thuret, Erika Hooker, Peter Quicke, Kevin Lanthier, Kalonji Ntumba, Irene M. Aspalter, Marina Uroz, Shane P. Herbert, Christopher S. Chen, Bruno Larrivée, and Katie Bentley. Bmp9 regulates notch signaling and the temporal dynamics of angiogenesis via lunatic fringe. bioRxiv, Sep 2026. URL: https://doi.org/10.1101/2023.09.25.557123, doi:10.1101/2023.09.25.557123. This article has 11 citations.
(ristori2026bmp9regulatesnotch pages 3-5): Tommaso Ristori, Raphael Thuret, Erika Hooker, Peter Quicke, Kevin Lanthier, Kalonji Ntumba, Irene M. Aspalter, Marina Uroz, Shane P. Herbert, Christopher S. Chen, Bruno Larrivée, and Katie Bentley. Bmp9 regulates notch signaling and the temporal dynamics of angiogenesis via lunatic fringe. bioRxiv, Sep 2026. URL: https://doi.org/10.1101/2023.09.25.557123, doi:10.1101/2023.09.25.557123. This article has 11 citations.
(ristori2026bmp9regulatesnotch pages 1-3): Tommaso Ristori, Raphael Thuret, Erika Hooker, Peter Quicke, Kevin Lanthier, Kalonji Ntumba, Irene M. Aspalter, Marina Uroz, Shane P. Herbert, Christopher S. Chen, Bruno Larrivée, and Katie Bentley. Bmp9 regulates notch signaling and the temporal dynamics of angiogenesis via lunatic fringe. bioRxiv, Sep 2026. URL: https://doi.org/10.1101/2023.09.25.557123, doi:10.1101/2023.09.25.557123. This article has 11 citations.
(ristori2026bmp9regulatesnotch pages 7-9): Tommaso Ristori, Raphael Thuret, Erika Hooker, Peter Quicke, Kevin Lanthier, Kalonji Ntumba, Irene M. Aspalter, Marina Uroz, Shane P. Herbert, Christopher S. Chen, Bruno Larrivée, and Katie Bentley. Bmp9 regulates notch signaling and the temporal dynamics of angiogenesis via lunatic fringe. bioRxiv, Sep 2026. URL: https://doi.org/10.1101/2023.09.25.557123, doi:10.1101/2023.09.25.557123. This article has 11 citations.
(ristori2026bmp9regulatesnotch pages 5-7): Tommaso Ristori, Raphael Thuret, Erika Hooker, Peter Quicke, Kevin Lanthier, Kalonji Ntumba, Irene M. Aspalter, Marina Uroz, Shane P. Herbert, Christopher S. Chen, Bruno Larrivée, and Katie Bentley. Bmp9 regulates notch signaling and the temporal dynamics of angiogenesis via lunatic fringe. bioRxiv, Sep 2026. URL: https://doi.org/10.1101/2023.09.25.557123, doi:10.1101/2023.09.25.557123. This article has 11 citations.
(ristori2026bmp9regulatesnotch pages 11-13): Tommaso Ristori, Raphael Thuret, Erika Hooker, Peter Quicke, Kevin Lanthier, Kalonji Ntumba, Irene M. Aspalter, Marina Uroz, Shane P. Herbert, Christopher S. Chen, Bruno Larrivée, and Katie Bentley. Bmp9 regulates notch signaling and the temporal dynamics of angiogenesis via lunatic fringe. bioRxiv, Sep 2026. URL: https://doi.org/10.1101/2023.09.25.557123, doi:10.1101/2023.09.25.557123. This article has 11 citations.
(gong2023apancanceranalysis pages 12-14): Xun Gong, Chenglong Zheng, Haiying Jia, Yangruiyu Liu, Rui Yang, Zizhou Chen, Yihang Pan, Xiaowu Li, and Yuchen Liu. A pan-cancer analysis revealing the role of lfng, mfng and rfng in tumor prognosis and microenvironment. BMC Cancer, Nov 2023. URL: https://doi.org/10.1186/s12885-023-11545-3, doi:10.1186/s12885-023-11545-3. This article has 9 citations and is from a peer-reviewed journal.
(chung2025lfngexpressingcentroacinarcell pages 3-4): Wen-Cheng Chung, Shubing Zhang, Azeddine Atfi, and Keli Xu. Lfng-expressing centroacinar cell is a unique cell-of-origin for p53 deficient pancreatic cancer. Oncogene, 44:348-362, Nov 2025. URL: https://doi.org/10.1038/s41388-024-03226-7, doi:10.1038/s41388-024-03226-7. This article has 2 citations and is from a domain leading peer-reviewed journal.